Objective: The Biohit SARS-CoV-2 IgM/IgG antibody kit (Biohit Healthcare, Hefei, China) is a novel rapid immunochromatog. test for the qual. detection of SARS-CoV-2 antibodies in human blood. It is intended to aid in identifying a prior infection within 20 min, can be obtained from capillary sampling, and was found to have a sensitivity and specificity of over 95% in the detection of antibodies two weeks after COVID-19 infection in a non-pregnant patient. Our aim was to assess the presence of antibodies at birth by the Biohit rapid test, in women vaccinated during pregnancy with the BNT162b2 mRNA COVID-19 Pfizer vaccine. Study Design: This prospective observational study included women admitted to the delivery room at least 7 days from their 2nd vaccine and who were not previously infected with COVID-19. Prior to delivery maternal blood was tested by the Biohit rapid test and compared to a quant. SARS-CoV-2 IgG antibody test taken concomitantly at birth. Results: Between June 2021 and July 2021, 60 women were recruited. Antibody titer levels were measured for 60 women at mean ± SD gestational age of 39.1 ± 1.2 wk with 100% of the tests resulting pos. The mean ± SD duration from the 2nd vaccine to delivery was 15.2 ± 2.4 wk. The median (range) level of IgG antibodies at birth was 1153.1 (146.6-4266.2) AU/mL for the parturients .59 of 60 (98.3%) Biohit rapid tests were pos. at birth. The one patient which returned neg. on the rapid test received the 2nd vaccine at 21 wk of gestation, resulting in a time interval 18.1 wk from the second vaccination to delivey, and had an IgG level of 146.6 AU/mL. Conclusion: The Biohit SARS-CoV-2 antibody qual. rapid test was found to be accurate among women at birth who were exposed to the mRNA COVID-19 vaccination during pregnancy. Since the rapid test is less expensive, can offer the clinician quicker reliable results from capillary sampling, and can be used with no need for complex settings in laboratories, the use of this novel diagnostic test should be considered in community health care centers and in the developing world.